Instant Solutions for Self-Medication
Simple, stable, and easy-to-use autoinjectors for (real) life.
Want to be a part of the instant solution? Join our team!
What began as a quest for a better epinephrine autoinjector has become a much bigger mission—to unleash unlimited possibilities for patients, families, and medications through temperature-resilient pharmaceutical solutions.
How are we different?
Our wet/dry medication delivery technology revolutionizes the capabilities of both the device and the medicine it contains. We do this by stabilizing and simplifying the treatment options for anaphylaxis, diabetes, cyanide exposure, opioid addiction, and more.
Our mixing mechanisms automate and control this process and are designed to protect the medication, the patient experience, and the outcome
Peace of mind in your pocket
Our compact medical delivery devices are uniquely designed to improve reaction times, reduce user errors, and put a full, confident life within reach.
Reliable and ready for everything.
Our wet-dry autoinjectors contain drugs in their most stable state, offering unprecedented shelf life and temperature resilience.
Our drug delivery devices are designed to reduce the impact of external variables—user error, heat, time — and provide consistent accuracy with every dose.
One study indicates anaphylaxis affects 1 in 50 Americans. Other studies believe it’s closer to 1 in 20.
– Asthma and Allergy Foundation of America
Caring for children with food allergies costs U.S. families $25 billion annually.
– JAMA Pediatrics
Each year in the United States, 200,000 people require emergency medical care for allergic reactions to food.
– FARE Food Allergy Research and Education
Partner With Us
With 85+ issued patents in 17 patent families, we’re currently seeking pharmaceutical partners to advance our commercialization pipeline and improve patient access to life-changing treatment options.
Drug Delivery PlatformS
Windgap Medical, Inc. announced today that it has a strategic partnership with ALK-Abelló, A/S ("ALK") to commercialize the company's epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.
"Windgap's drug delivery platform has the potential to positively impact the healthcare industry by addressing stability issues experienced by patients where drugs are highly sensitive to the environment," said Lily Yeung, vice president, Molex Ventures.
The Massachusetts Life Sciences Center (MLSC), a quasi-public agency charged with implementing the state’s 10-year, $1-billion Life Sciences Initiative, announced today the awarding of $2 million in loans to two early-stage life sciences companies.
Some statements are forward-looking. Unless specifically stated, these products are not approved for sale in the United States or the European Union.